This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2023 May;103(5):994-995.

doi: 10.1016/j.kint.2023.02.014.

The authors reply

Jonathan Barratt¹, Brad H Rovin²; NefIgArd Investigators

Affiliations

Affiliations

¹ College of Medicine, Biological Sciences, and Psychology, University of Leicester, Leicester, UK.
² Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Electronic address: Brad.Rovin@osumc.edu.

PMID: 37085260
DOI: 10.1016/j.kint.2023.02.014

Comment

The authors reply

Jonathan Barratt et al. Kidney Int. 2023 May.

. 2023 May;103(5):994-995.

doi: 10.1016/j.kint.2023.02.014.

Authors

Jonathan Barratt¹, Brad H Rovin²; NefIgArd Investigators

Affiliations

¹ College of Medicine, Biological Sciences, and Psychology, University of Leicester, Leicester, UK.
² Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Electronic address: Brad.Rovin@osumc.edu.

PMID: 37085260
DOI: 10.1016/j.kint.2023.02.014

No abstract available

PubMed Disclaimer

Comment on

Is the NefIgArd trial a paradigm shift in the treatment of IgA nephropathy?
Gutiérrez E, Caravaca-Fontán F, Sevillano Á. Gutiérrez E, et al. Kidney Int. 2023 May;103(5):994. doi: 10.1016/j.kint.2023.02.011. Kidney Int. 2023. PMID: 37085261 No abstract available.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science